Pleomorphic Xanthoastrocytoma
9
4
5
3
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
11.1%
1 terminated out of 9 trials
75.0%
-11.5% vs benchmark
11%
1 trials in Phase 3/4
33%
1 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (9)
Pediatric Long-Term Follow-up and Rollover Study
Evaluation of Hippocampal-Avoidance Using Proton Therapy in Low-Grade Glioma
Comprehensive Analysis of Chemotherapy and Targeted Therapy Outcomes in Recurrent Malignant Gliomas
Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
Pediatric Low Grade Glioma - MEKinhibitor TRIal vs Chemotherapy
A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas
Social Determinants of Health in Glioblastoma Population
Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors
A Biospecimen Collection Study in BRAF-V600E Mutated Recurrent Gliomas